Biocartis, Merck to Develop Liquid Biopsy RAS Biomarker Test for Colorectal Cancer | GenomeWeb

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis announced today that it has signed an agreement with Germany's Merck to develop and commercialize a new liquid biopsy-based RAS biomarker test for metastatic colorectal cancer based on its Idylla PCR-based diagnostics platform.

According to Biocartis, the new test will comprise two Idylla cartridges and be designed to detect an extended panel of RAS mutations while also providing a BRAF V600 mutation analysis, allowing clinicians to evaluate the mutation status of both biomarker types simultaneously.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.